- Conditions
- Metastatic Cancer, Melanoma, Colon Cancer, Differentiated Thyroid Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Metastatic Melanoma, HCC, Metastatic Colon Cancer
- Interventions
- Solar Simulator
- Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1465–1488
of 2,054
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma, Advanced or Metastatic Solid Tumors
- Interventions
- Cavrotolimod, Pembrolizumab, Cemiplimab
- Drug · Biological
- Lead sponsor
- Exicure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Orange, California • San Francisco, California + 21 more
- Conditions
- Iris Tumor
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Melanoma
- Interventions
- MORAb028
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Pigmented Skin Lesion, Melanoma
- Interventions
- Functional photoacoustic microscopy, Standard of care surgical excision, Single cell photoacoustic microscopy
- Device · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Recurrent Melanoma, Stage IV Skin Melanoma
- Interventions
- Recombinant Interferon Alfa, Bevacizumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- recombinant interferon gamma
- Biological
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Breast Cancer
- Interventions
- IDC-G305
- Biological
- Lead sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2024
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Metastatic Cancer, Melanoma
- Interventions
- Vemurafenib, Young TIL, Cyclophosphamide, Fludarabine, Aldesleukin
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- Binimetinib, Imatinib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • San Francisco, California
- Conditions
- Melanoma
- Interventions
- dendritic cell-MART-1 peptide vaccine, leukapheresis
- Biological · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Melanoma
- Interventions
- Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Melanoma
- Interventions
- AZD6244, Dacarbazine, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Boston, Massachusetts
- Conditions
- Melanoma
- Interventions
- Pegylated Interferon-Alfa 2b (PEG Intron), GP-100 Peptide Vaccine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, gp209-2M antigen, incomplete Freund's adjuvant
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-melanoma Skin Cancer
- Interventions
- HP802-247, Bacitracin Ointment
- Biological
- Lead sponsor
- Healthpoint
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Melanoma
- Interventions
- Indocyanine Green (IC-Green), Imaging
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma
- Interventions
- Lerapolturev, Anti-PD-1 Checkpoint Inhibitor
- Biological
- Lead sponsor
- Istari Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Orlando, Florida • Chicago, Illinois + 9 more
- Conditions
- Melanoma, Skin Cancer
- Interventions
- Surveys & Mailed Materials
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
- Interventions
- Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Sentinel Lymph Node, Melanoma (Skin), Breast Cancer
- Interventions
- IC-Green KIT
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Poughkeepsie, New York • Hershey, Pennsylvania
- Conditions
- Metastatic Melanoma
- Interventions
- High Dose Interleukin-2 (IL-2), ACT with TIL Infusion, Vemurafenib, Lymphodepletion
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma
- Interventions
- dacarbazine, CP-675,206, temozolomide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 655 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 55
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 45 more